SHANGHAI -- Chinese drugmaker CanSino Biologics is accelerating clinical trials for its coronavirus vaccine even as earnings remained in the red.
The Hong Kong and Shanghai-listed company on Friday reported a net loss of 102 million yuan ($15 million) on the back of zero revenue since it has yet to commercialize any products.
